Patent: 8,337,847
✉ Email this page to a colleague
Summary for Patent: 8,337,847
Title: | Methods of treating anemia using anti-IL-6 antibodies |
Abstract: | The invention provides methods of treating anemia in patients in need thereof, particularly in patients having anemia associated with chronic and/or inflammatory conditions such as cancers and arthritic conditions by administering antibodies or antibody fragments that bind IL-6. The treatment methods result in increased hemoglobin. |
Inventor(s): | Smith; Jeffrey T. L. (Redmond, WA), Latham; John (Seattle, WA), Litton; Mark (Seattle, WA), Schatzman; Randall (Redmond, WA) |
Assignee: | AlderBio Holdings LLC (Las Vegas, NV) |
Application Number: | 12/624,816 |
Patent Claims: | see list of patent claims |
Details for Patent 8,337,847
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2028-11-25 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2028-11-25 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2028-11-25 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2028-11-25 |
Genentech, Inc. | OCREVUS | ocrelizumab | Injection | 761053 | 03/28/2017 | ⤷ Try a Trial | 2028-11-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |